## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `tb-500`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/tb-500/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/tb-500/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/tb-500/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `tb-500` v44 · content_hash `65bf4c2e030b0b3a…` · thread_head genesis · 25 DIVs
- **thesis (c1):** TB-500 is a synthetic version of thymosin beta-4, the body's principal G-actin-sequestering peptide, which regulates the actin dynamics that govern cell migration — the molecular basis for its role in tissue repair.
  - c2 [mechanistic/active] The same seven-amino-acid actin-binding motif that gives Tb4 its structural function also drives angiogenesis and endothelial migration, so new blood-vessel gro
  - c3 [preclinical/active] In controlled animal wound models, Tb4 accelerated skin regeneration (reepithelialization up 42-61%) while increasing collagen deposition and angiogenesis.
  - c4 [human/active] Tb4 reached genuine randomized, double-blind, placebo-controlled human trials for chronic wounds (pressure and venous stasis ulcers), where it was safe but did 
  - c5 [human/active] The ophthalmic Tb4 formulation RGN-259 showed positive Phase II human efficacy for dry-eye signs and symptoms via corneal epithelial repair — the strongest cont
  - c6 [preclinical/active] In preclinical cardiac injury, both local and systemic Tb4 dosing reduced infarct size and improved function via cardiomyocyte survival (ILK/Akt) and angiogenes
  - c7 [preclinical/active] Tb4 improved ligament healing histologically and mechanically in a rat MCL model, but a 2026 scoping review confirms tendon, ligament, muscle and spine/disc evi
  - c8 [human/active] Across multiple chronic human wound types Tb4 has been reported to promote faster repair, extending its regenerative case into diseased human tissue.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/tb-500/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/tb-500/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `tb-500`
- **title:** TB-500 (Thymosin Beta-4)
- **url:** https://miscsubjects.com/a/tb-500
- **register:** essay
- **updated:** 2026-07-24T17:41:57.461Z
- **tags:** peptide, tb-500, thymosin-beta-4, disc

## Body

TB-500 is sold as a healing peptide, and the first thing to understand is that "TB-500" and the peptide in the actual research trials are usually not the same molecule. The trials used full-length thymosin beta-4 (Tβ4), a 43-amino-acid protein the body makes in nearly every tissue. Most vials sold as "TB-500" contain a synthetic fragment — the acetylated seven-amino-acid piece (Ac-LKKTETQ) that holds the actin-binding activity — chosen because it's cheaper to make. That single fact reshapes how you should read every efficacy and safety claim below. This page covers what Tβ4 actually does, what has and hasn't been shown in humans, the fragment problem, real dosing and reconstitution, the cancer question that defines its risk, its ban in sport, and where it sits in a disc-recovery stack. Zero prior knowledge assumed.

## What it actually is

Thymosin beta-4 is the body's main G-actin-sequestering peptide. Actin is the protein a cell uses to build and tear down its internal skeleton; controlling that is how a cell changes shape and crawls. Tβ4 binds actin monomers one-to-one and regulates that machinery, which is why it shows up wherever tissue is rebuilding — wounds, healing heart, migrating repair cells.

## TB-500 is not thymosin beta-4 — read this before anything else

The distinction is routinely buried by vendors and it is central:

- **Thymosin beta-4 (Tβ4):** the full 43-amino-acid protein used in every legitimate human and animal trial (IV cardiac, RGN-259 eye drops, wound studies).
- **"TB-500":** a marketed synthetic fragment, the acetylated heptapeptide Ac-LKKTETQ (residues 17-23, ~889 Da), sold as a stable, cheaper stand-in. It reproduces the actin-binding activity but is not the molecule trialed clinically.

[[embed:source:s17]]

To make it worse, full-length Tβ4 is also cleaved in the body to a different active fragment (Ac-SDKP), and some products sold as "TB-500" actually contain that instead. So "TB-500" is not even one consistent substance across vendors — you often cannot know which molecule you received. Efficacy and safety data for full Tβ4 cannot simply be assumed to transfer to whatever is in the vial.

## One short motif does the healing

The repair-relevant part of Tβ4 is that seven-amino-acid actin-binding motif, and the same motif drives angiogenesis and endothelial cell migration — the growth of new blood vessels.

[[embed:source:s1]]

That matters for a disc because tendon, ligament, and disc are poorly vascularized, and blood supply is the rate-limiter on healing them. A repair mechanism that is intrinsically pro-angiogenic is aimed straight at that bottleneck. On paper.

## The human record: one clear win, several honest misses

In animal wound models the effect is clean — topical or systemic Tβ4 sped skin regrowth by 42-61% while adding collagen and vessels.

[[embed:source:s2]]

In humans, full Tβ4 went into proper randomized, placebo-controlled trials for chronic wounds (pressure ulcers, venous stasis ulcers). Honest result: safe and well tolerated, but the primary healing endpoints did not reach statistical significance.

[[embed:source:s3]]

The one indication where human data turned clearly positive is the eye. The ophthalmic formulation RGN-259 significantly improved dry-eye signs and symptoms versus placebo in Phase 2 trials.

[[embed:source:s18]]

So the truthful summary is narrow: one positive human indication (dry eye), wound trials that were safe but unproven, and — for tendon, ligament, muscle, and disc — no confirmatory human trial at all.

[[embed:source:s10]]

## Heart, stroke, ligament: the preclinical case

The animal repair record is broad and consistent with the mechanism. After a heart attack, Tβ4 given locally and systemically shrank infarct size and improved function via cell-survival pathways (ILK/Akt) with less scarring — and the systemic result matters, because it shows the peptide reaches a distant injury and acts there.

[[embed:source:s9]]

In a rat embolic stroke it improved neurological outcome through remyelination and axonal remodeling.

[[embed:source:s19]]

And in the tissue class closest to a disc stack, it improved ligament healing (rat MCL) both structurally and mechanically.

[[embed:source:s11]]

## How people dose and reconstitute it

No human dose-finding trial of the TB-500 fragment exists, so every protocol is practitioner/anecdotal — folklore, not medicine.

- **Dose (anecdotal):** a loading phase around 4-6 mg per week (split into two injections) for 4-6 weeks, then maintenance ~2-2.5 mg weekly or every other week, total cycle 8-12 weeks, then time off. These mg-scale numbers apply to the fragment; the full-Tβ4 trials dosed completely differently (e.g. micrograms/kg IV in the cardiac trial), so the anecdotal mg figures have no validated basis.
- **Route:** subcutaneous or intramuscular injection; no oral activity (it's digested).
- **Reconstitution:** lyophilized powder mixed with bacteriostatic water; swab the stopper, run diluent down the wall, swirl — don't shake. Refrigerate at 2-8 °C, protect from light, avoid freeze-thaw; commonly cited stable ~28 days once mixed. These are vendor guidelines, not pharmacopeial stability data.

## The cancer question — this is the real safety story

Here the angiogenesis mechanism cuts against it. Tβ4 is overexpressed in many solid tumors, and there it is associated with more migration, metastasis, and blood-vessel growth.

[[embed:source:s20]]

The literature is genuinely two-directional — in multiple myeloma Tβ4 behaves as a tumor suppressor — but the practical point stands: the same pro-angiogenic, pro-migration activity that plausibly helps a healing tendon is the activity implicated in tumor progression.

[[embed:source:s21]]

The sane default that falls out of this: treat active malignancy or a significant cancer history as a contraindication. This is a sharper safety concern than BPC-157 carries, where the tumor evidence actually points the other way.

## Banned in sport, and heavily policed

If you compete in anything drug-tested, stop here. TB-500/Tβ4 is on the WADA Prohibited List, banned at all times under the peptide-hormones/growth-factors section via its catch-all language.

[[embed:source:s12]]

It's not theoretical enforcement: it became infamous in the Australian NRL supplements scandal, it's a well-known horse-racing dope, and athletes have taken multi-year bans for it.

## What people report

The anecdote layer runs almost entirely through BPC-157 + TB-500 stacks, and it's specifically the tendon-and-back crowd — torn biceps and forearm tendons, chronic Achilles and patellar tendinitis, and sacral/back pain.

[[embed:source:s15]]

[[embed:source:s16]]

Uncontrolled, confounded, self-selected, and — given the fragment problem — often not even a known molecule. Real people, not real evidence.

## Where it fits for the spine

In the stack, TB-500 is the systemic repair signal that complements BPC-157's more locally-studied effects; both push angiogenesis and cell migration into the poorly-vascularized tissue a disc is made of, and Tβ4's anti-fibrotic bias (repair over scar) is the appealing part. But it is theory stacked on an identity problem: no one has tested TB-500 against a human disc, the fragment may not match the trialed molecule, and the cancer-mechanism caution is real. It belongs in the framework in the disc-stack, herniated-disc, and degenerative-disc-disease pages — with those caveats attached, not stripped off.

## Proven, unproven, and the catch

Proven: Tβ4 regulates actin and drives angiogenesis; it heals animal wounds and improves human dry eye in an RCT; it's anti-fibrotic and reaches distant injuries systemically in animals. Unproven: that it heals tendon, ligament, or disc in people. The catch specific to this compound: the product sold as "TB-500" is usually a fragment, not the trialed protein, so even the transferable evidence may not apply to what's in the syringe. And the angiogenesis that helps healing is the same mechanism that argues against use in cancer.

*Not medical advice. TB-500 is sold for research use only, is not an approved treatment, and is banned in tested sport. Nothing here is a dosing or treatment recommendation.*


## Claims (10)

- **c4** [human w=?] Tb4 reached genuine randomized, double-blind, placebo-controlled human trials for chronic wounds (pressure and venous stasis ulcers), where it was safe but did not hit statistical significance on primary healing endpoints.
  - sources: s3, s4, s5
- **c5** [human w=?] The ophthalmic Tb4 formulation RGN-259 showed positive Phase II human efficacy for dry-eye signs and symptoms via corneal epithelial repair — the strongest controlled human efficacy signal for the peptide.
  - sources: s7
- **c8** [human w=?] Across multiple chronic human wound types Tb4 has been reported to promote faster repair, extending its regenerative case into diseased human tissue.
  - sources: s13
- **c9** [human w=?] TB-500 and thymosin beta-4 are on the WADA Prohibited List and banned at all times for competitive athletes.
  - sources: s12
- **c3** [preclinical w=?] In controlled animal wound models, Tb4 accelerated skin regeneration (reepithelialization up 42-61%) while increasing collagen deposition and angiogenesis.
  - sources: s2
- **c6** [preclinical w=?] In preclinical cardiac injury, both local and systemic Tb4 dosing reduced infarct size and improved function via cardiomyocyte survival (ILK/Akt) and angiogenesis.
  - sources: s8, s9
- **c7** [preclinical w=?] Tb4 improved ligament healing histologically and mechanically in a rat MCL model, but a 2026 scoping review confirms tendon, ligament, muscle and spine/disc evidence remains overwhelmingly animal-stage with no confirmatory human musculoskeletal trials.
  - sources: s11, s10
- **c1** [mechanistic w=?] TB-500 is a synthetic version of thymosin beta-4, the body's principal G-actin-sequestering peptide, which regulates the actin dynamics that govern cell migration — the molecular basis for its role in tissue repair.
  - sources: s1, s4
- **c2** [mechanistic w=?] The same seven-amino-acid actin-binding motif that gives Tb4 its structural function also drives angiogenesis and endothelial migration, so new blood-vessel growth is intrinsic to how it repairs tissue.
  - sources: s1
- **c10** [anecdotal w=?] Real-world users self-treating tendon, tendinitis and spine/sacral injuries with TB-500 (usually stacked with BPC-157) report reduced pain and improved range of motion, but these are uncontrolled, confounded anecdotes.
  - sources: s14, s15, s16

## Voxel graph (10 atoms · 17 edges)
- full graph: https://miscsubjects.com/api/articles/tb-500/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (20)
- chain valid: no · head: ``

### s1 · pubmed
- title: The actin binding site on thymosin beta4 promotes angiogenesis
- url: https://pubmed.ncbi.nlm.nih.gov/14500546/
- quote: we find that a seven amino acid actin binding motif of thymosin beta4 is essential for its angiogenic activity.
- claim_ids: c1, c2
- hash: ``

### s2 · pubmed
- title: Thymosin beta4 accelerates wound healing
- url: https://pubmed.ncbi.nlm.nih.gov/10469335/
- quote: Addition of Tbeta4 topically or intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61% at 7 d post-wounding.
- claim_ids: c3
- hash: ``

### s3 · pubmed
- title: Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers
- url: https://clinicaltrials.gov/study/NCT00382174
- quote: evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers
- claim_ids: c4
- hash: ``

### s4 · pubmed
- title: Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
- url: https://clinicaltrials.gov/study/NCT00832091
- quote: a synthetically-produced copy of a naturally occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.
- claim_ids: c1, c4
- hash: ``

### s5 · pubmed
- title: Thymosin beta-4 and venous ulcers: a European prospective, randomized study
- url: https://pubmed.ncbi.nlm.nih.gov/17495250/
- quote: When review safety data show no-dose-limiting adverse events, a new group will be enrolled.
- claim_ids: c4
- hash: ``

### s7 · pubmed
- title: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial
- url: https://pubmed.ncbi.nlm.nih.gov/26056426/
- quote: This study confirms the efficacy of 0.1% Tbeta4 as a topical treatment for relief of signs and symptoms of dry eye.
- claim_ids: c5
- hash: ``

### s8 · pubmed
- title: Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/
- quote: Tbeta4 administered throughout the study reduced infarct size and resulted in significant improvements in hemodynamic performance.
- claim_ids: c6
- hash: ``

### s9 · pubmed
- title: Thymosin beta4 is cardioprotective after myocardial infarction
- url: https://pubmed.ncbi.nlm.nih.gov/17600280/
- quote: thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function.
- claim_ids: c6
- hash: ``

### s10 · pubmed
- title: Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
- url: https://doi.org/10.3390/app16126202
- quote: the evidence base is heavily weighted toward preclinical and mechanistic work, with human musculoskeletal data sparse
- claim_ids: c7
- hash: ``

### s11 · pubmed
- title: Thymosin beta4 enhances the healing of medial collateral ligament injury in rat
- url: https://pubmed.ncbi.nlm.nih.gov/23523891/
- quote: Local administration of Tbeta4 promotes the healing process of MCL, both histologically and mechanically, in a rat model.
- claim_ids: c7
- hash: ``

### s12 · news
- title: TB-500 - Status, Risks, and Bans in Sport and Military
- url: https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
- quote: The World Anti-Doping Agency (WADA) lists TB-500 under 'Growth Factors and Growth Factor Modulators' as a prohibited substance
- claim_ids: c9
- hash: ``

### s13 · pubmed
- title: Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries
- url: https://pubmed.ncbi.nlm.nih.gov/31649007/
- quote: Thymosin beta4 promotes faster repair in various chronic human wounds, including pressure ulcers, stasis ulcers, and epidermolysis bullosa lesions.
- claim_ids: c8
- hash: ``

### s14 · reddit
- title: Initial impressions with BPC-157 and TB-500 for tendon repair
- url: https://www.reddit.com/r/Peptides/comments/ypyy1v/initial_impressions_with_bpc157_and_tb500_for/
- quote: Inflammation and pain is significantly reduced. ROM is improving for repaired bicep. Unfortunately no control for comparison.
- claim_ids: c10
- hash: ``

### s15 · reddit
- title: BPC 157 / TB 500 tendinitis experience
- url: https://www.reddit.com/r/Peptides/comments/1cnx3vj/bpc_157_tb_500_tendinitis_experience/
- quote: I would strongly and without reservation recommend this combo to anyone with tendinitis. Remember that you still have to do the work though!
- claim_ids: c10
- hash: ``

### s16 · reddit
- title: My story and BPC-157/TB-500, GHRP-2 observations so far
- url: https://www.reddit.com/r/Peptides/comments/sjml9z/my_story_and_bpc157tb500_ghrp2_observations_so_far/
- quote: chronic pain without trauma or known cause since 1 year ago. Started out in my sacrum (specifically S5 segment)
- claim_ids: c10
- hash: ``

### s17 · news
- title: TB-500 - Status, Risks, and Bans (BSCG)
- url: https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military
- quote: TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) that corresponds to amino acids 17-23 of thymosin beta-4
- hash: ``

### s18 · pubmed
- title: Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015)
- url: https://pubmed.ncbi.nlm.nih.gov/25826322/
- quote: RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P = 0.0141)
- hash: ``

### s19 · pubmed
- title: Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke
- url: https://pubmed.ncbi.nlm.nih.gov/20627173/
- quote: Tbeta4 improves neurological functional outcome after embolic stroke in rats.
- hash: ``

### s20 · pubmed
- title: Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003)
- url: https://pubmed.ncbi.nlm.nih.gov/14625258/
- quote: Thymosin beta4 may stimulate tumor metastasis by activating cell migration and angiogenesis.
- hash: ``

### s21 · pubmed
- title: Thymosin beta4 has tumor suppressive effects in multiple myeloma
- url: https://pubmed.ncbi.nlm.nih.gov/19833631/
- quote: Tbeta4 overexpression led to significantly decreased proliferative and migratory capacities and increased sensitivity to apoptosis-induction.
- hash: ``

## Provenance (63 model passes)
- chain valid: yes · head: `5fec39af3770cd4c`

- ask · grok/grok-4.3 · 2026-07-07T03:48 · hash `7808a4c6229e`
- ask · grok/grok-4.3 · 2026-07-07T03:50 · hash `3771fced9dc2`
- ask · grok/grok-4.3 · 2026-07-07T04:07 · hash `e7abd0ef1b6b`
- ask · grok/grok-4.3 · 2026-07-07T04:09 · hash `9719fc186d02`
- ask · grok/grok-4.3 · 2026-07-07T04:40 · hash `bb95d6973c57`
- ask · grok/grok-4.3 · 2026-07-07T05:18 · hash `562b241572f7`
- ask · grok/grok-4.3 · 2026-07-11T14:38 · hash `629b2c9bee5e`
- voxel_divide · owner · 2026-07-17T02:42 · hash `5fec39af3770`

## Question graph
- questions: 8 · evidence ingests: 2
- **qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446** [answered] SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No imaging-confirmed outcomes; no long-term follow-up; no interaction data specific to herniated-disc patients or common spine medications.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: No controlled human trials for herniated-disc outcomes; No data on BPC-157/TB-500 interactions or safety in disc pathology; No coverage of other peptides (e.g., ARA-290) for herniated discs in the provided slugs
- **qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4** [gap] SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?
  - gaps: No interaction_risk or limitations-slot claims available; No dosing, patient-specific, or combination safety data; Human orthopaedic and systemic data lacking per s6
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7** [enriched] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No controlled human data for herniated discs; anecdotes are n=1, self-reported, no imaging follow-up.
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319** [enriched] SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?
  - gaps: no human controlled data for disc herniation; no interaction data; no ARA-290 or TB-500 herniated-disc coverage in topology; long-term safety absent
- **qn_tb_500_selftest_graph_what_is_documented_about_t_6e5d6ef8** [answered] SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?
- **qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6** [gap] SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?
  - gaps: No human imaging follow-up data; No controlled trials for disc herniation; Long-term safety unknown

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/tb-500/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/tb-500/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"tb-500","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest tb-500|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim tb-500|tier|assertion`
- **iMessage ask:** `tb-500|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `tb-500`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*